FDA grants capmatinib priority review in NSCLC indication

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has granted Priority Review to capmatinib’s (INC280) New Drug Application.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login